PTPRC and acute myeloid leukemia: At day 45 after cell transfer, flow cytometry evaluation of the circulating human CD45+ cells in the murine PB was perfomed to assess AML engraftment showing that BKM120-treated mice carried significantly lower leukemia burden in the PB in comparison to the vehicle-treated group (Fig. 8C).